Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

January 13, 2017

Study Completion Date

January 13, 2017

Conditions
Ovarian CancerFallopian Tube CancerEndometrial CancerSolid Tumors
Interventions
DRUG

STM 434

STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.

DRUG

Liposomal doxorubicin

Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

37203

Sarah Cannon Research Institute, Nashville

78229

South Texas Accelerated Research Therapeutics, San Antonio

02114

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Santa Maria Biotherapeutics

INDUSTRY

NCT02262455 - Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors | Biotech Hunter | Biotech Hunter